The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
The Japanese company's shares hit a new closing high, driven by growing hopes for its games segment and other entertainment businesses. The companies said production is planned to start by end of 2026 ...
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head of Swiss Re’s life and health reinsurance arm said.
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Novo Nordisk got European approval to move forward with its planned buyout of U.S.-based drug manufacturer Catalent, which produces much of its popular obesity drug Wegovy. That leaves the U.S.